Phase II Study Evaluating HSV-tk + Valacyclovir Gene Therapy in Combination With Androgen Deprivation Therapy, Brachytherapy, External Beam Radiotherapy, and Prostatectomy for High-Risk Prostate Cancer
Phase of Trial: Phase II
Latest Information Update: 04 Jan 2019
Price : $35 *
At a glance
- Drugs Aglatimagene besadenovec (Primary) ; Bicalutamide (Primary) ; Leuprorelin (Primary) ; Valaciclovir (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 04 Jan 2019 According to a Candel Therapeutics media release, the company has received the Series B financing from PBM Capital Group, for Active Surveillance of this study.
- 24 Oct 2018 Status changed from not yet recruiting to recruiting.
- 24 Aug 2018 Planned initiation date changed from 1 Jul 2018 to 1 Aug 2018.